EICHORCondition: Small-cell Lung Cancer · Sponsor: Norwegian University of Science and Technology
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Studies have shown that combining chemotherapy and immune checkpoint inhibitors (ICI) prolongs survival compared with chemotherapy alone in extensive stage small-cell lung cancer (ES SCLC), but the survival benefit is modest. The main aim of this trial is to investigate whether there is a synergistic/additive effect of concurrent thoracic radiotherapy in ES SCLC patients receiving carboplatin/etoposide/durvalumab.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. Age \> 18 years at time of study entry 2. ECOG performance status of 0 or 1 3. Body weight \>30 kg 4. Adequate bone marrow, liver and kidney function 5. Life expectancy of at least 3 months 6. At least one measurable (RECIST 1.1), thoracic lesion that can be irradiated with 30 Gy/10 fractions 7. Histologically or cytologically confirmed SCLC 8. Stage III-IV disease (TNM v8) 9. FEV1 \>1 L or \>30 % of predicted value and DLCO \>30 % of predicted value 10. Patients with brain metastases are eligible provided they are asymptomatic or treated and stable on steroids and/or anticonvulsants prior to the start of treatment Exclusion Criteria: 1. Previous chemo-, immuno- or radiotherapy for SCLC 2. Major surgical procedure last 28 days 3. History of allogenic organ transplantation, autoimmune disease, immunodeficiency, hepatitis or HIV 4. Uncontrolled intercurrent illness 5. Other active malignancy 6. Leptomeningeal carcinomatosis 7. Immunosuppressive medication 8. Pregnant or breastfeeding women
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| North Estonia Medical Centre | Tallinn, Estonia | — |
| Landspitali University Hospital | Reykjavik, Iceland | — |
| Erasmus MC | Rotterdam, Netherlands | — |
| Ålesund Hospital | Ålesund, Norway | — |
| Haukeland Universitetssykehus | Bergen, Norway | — |
| Nordlandssykehuset HF | Bodø, Norway | — |
| Drammen sykehus - Vestre Viken | Drammen, Norway | — |
| Innlandet hospital Gjøvik | Gjøvik, Norway | — |
| Haugesund hospital | Haugesund, Norway | — |
| Sykehuset Levanger | Levanger, Norway | — |
| Akershus Universitetssykehus AHUS | Oslo, Norway | — |
| Oslo University Hospital Ullevål | Oslo, Norway | — |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05223647